Diabetes Severity Tied to Outcome in CRC Patients Undergoing Resection
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Oct. 23, 2023 -- The severity of diabetes is associated with outcomes among patients with stage I to III colorectal cancer (CRC) undergoing curative radical resection, according to a study published online Oct. 23 in Cancer.
Hsin-Yin Hsu, M.D., from the Taipei MacKay Memorial Hospital in Taiwan, and colleagues conducted a population-based retrospective cohort study using data registered between 2007 and 2015 in the Cancer Registry Database, which is linked to the National Health Insurance Research Database and National Death Registry. Patients with CRC who underwent curative radical resection for stage I to III disease were evaluated and subdivided according to diabetic status. The association between diabetes severity and CRC survival was examined.
Data were included for 59,202 patients with CRC. The researchers found that the group with diabetes without complications had insignificantly worse overall survival, disease-free survival, and cancer-specific survival compared with the no diabetes group, while the group with diabetes with complications had a significantly higher risk for poor survival. Compared with those without diabetes, patients with CRC and diabetes had a higher risk for recurrence. Important effect modifiers included sex and TNM staging.
"These findings indicate that preventing diabetes complications may help improve survival in patients with CRC," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease
FRIDAY, June 7, 2024 -- For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists...
Neoadjuvant Nivolumab, Ipilimumab Safe for dMMR Colon Cancer
WEDNESDAY, June 5, 2024 -- Neoadjuvant nivolumab plus ipilimumab has an acceptable safety profile in patients with locally advanced mismatch repair-deficient (dMMR) colon cancer...
Lowering FIT Positivity Thresholds Improves Sensitivity, Specificity
WEDNESDAY, June 5, 2024 -- Lowering the fecal immunochemical test (FIT) positive threshold yields levels of sensitivity and specificity that are comparable to those reported for...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.